Reduced Intensity Transplant Using Extracorporeal Photopheresis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00179790
Recruitment Status : Completed
First Posted : September 16, 2005
Last Update Posted : March 6, 2017
Information provided by (Responsible Party):
Jennifer Schneiderman, MD, Ann & Robert H Lurie Children's Hospital of Chicago

Brief Summary:

Stem cell transplantation may be used to cure childhood cancers, and other diseases. Traditionally, stem cell transplants use high doses of chemotherapy and radiation. This regimen may cause significant problems after transplant such as infertility, infection, and graft versus host disease (GVHD).

Reduced intensity transplant (RIT) uses medications which weaken the immune system, allowing donor cells to take over. The goal of a RIT is to reduce the risk for complications after transplant. Usually medication is used to weaken the immune system, but there are other options such as extracorporeal photopheresis (ECP) that may be less toxic.

ECP is currently used for the treatment of GVHD and certain lymphomas. ECP uses a machine that filters white blood cells from the blood, treats them with ultraviolet (UV) light, and then gives all the cells back to the patient. The patient's immune system becomes weaker, allowing the donor cells to replace those of the patient. Studies involving the use of ECP for conditioning have shown fewer side effects than the use of medications.

The primary purpose of this clinical research trial is to evaluate the safety and feasibility of ECP as part of a preparative regimen for RIT in children and young adults.

Condition or disease Intervention/treatment Phase
Leukemia Cancer Procedure: Extracorporeal Photopheresis Phase 1 Phase 2

Detailed Description:

This study tests the feasibility of a reduced intensity preparative regimen for stem cell transplant including extracorporeal photopheresis (ECP), busulfan, and fludarabine in patients with leukemia, lymphoma, and certain non-malignant diseases. The current reduced intensity protocol includes busulfan, fludarabine, and anti-thymocyte immunoglobulin. ECP is currently used in diseases such as chronic GVHD and cutaneous T cell lymphoma. The mechanism of ECP has not been defined. It is hypothesized that exposure of white blood cells to ultraviolet light with 8-methoxypsoralen initiates an apoptotic cellular cascade. Apoptotic cells are recognized and removed by the reticuloendothelial system, initiating the secretion of anti-inflammatory cytokines and the reduction of proinflammatory cytokines. Antigen presenting cells then regulate immune responses through the induction of tolerance.

Here we incorporate the use of ECP, fludarabine, and busulfan in the preparative regimen, followed by ECP as prophylaxis for acute graft versus host disease. We hypothesize that photopheresis is safe and feasible, and patients will have similar rates of engraftment with less GVHD as those treated with current reduced intensity protocols. The use of ECP prior to transplant provides immunosuppression promoting host engraftment. Furthermore, the introduction of ECP following transplant may be able to induce tolerance thereby reducing rates of GVHD.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Reduced Intensity Stem Cell Transplant in Children and Young Adults Utilizing Photopheresis, Fludarabine, and Busulfan
Study Start Date : July 2005
Actual Primary Completion Date : June 2010
Actual Study Completion Date : January 2015

Intervention Details:
    Procedure: Extracorporeal Photopheresis
    Patient will undergo ECP treatment pre and post stem cell transplant infusion

Primary Outcome Measures :
  1. To determine the feasibility of using photopheresis as the backbone of a reduced intensity transplant regimen to reduce transplant related mortality and acute and chronic graft versus host disease (GVHD) [ Time Frame: Throughout Treatment ]
  2. To determine time to engraftment and the percentage of patients achieving full engraftment by day +100. Engraftment will be defined as > 95% total donor chimerism as determined by restriction fragment length polymorphism (RFLP). [ Time Frame: By Day +100 ]
  3. To determine the rate of grades III and IV acute GVHD. [ Time Frame: Throughout Treatment ]
  4. To evaluate 100 day transplant related mortality [ Time Frame: Through Day +100 ]

Secondary Outcome Measures :
  1. To establish patterns of biological effects of photopheresis on dendritic cell and CD4/CD8 populations, CD4/CD25 populations, IFN-gamma, TNF-alpha, IL-10, IL-12, and IL-4 [ Time Frame: Pre Transplant through 1 year post stem cell transplant ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Weight > 25 kg
  • Patients with acute lymphoblastic leukemia (ALL) who are in CR (complete remission; < 5% blasts in bone marrow and no active central nervous system disease) who:

    • Are in second remission with an initial remission of < 36 months.
    • Patients with "high risk" disease in CR1, defined by karyotype abnormalities such as presence of (9;22) translocation, monosomy 7, or monosomy 5; and/or patients with slow initial response (initial remission not reached within four weeks from diagnosis).
    • Are in third (or subsequent) remission
    • Experience isolated extramedullary relapse while on therapy
    • Have experienced relapse following myeloablative stem cell transplant
    • Are WT1+ following induction therapy
  • Patients with acute myelogenous leukemia (AML) who:

    • Are in first remission and remain WT1 positive.
    • Are in second remission
    • Are in initial partial remission (< 20% blasts in bone marrow)
    • Experience relapse following myeloablative stem cell transplant
  • Patients with relapsed lymphoma whose residual disease appears to be chemo-responsive and non-bulky (< 5 cm largest diameter)
  • Patients with chronic myelogenous leukemia (CML) in chronic phase who:

    • Don't achieve remission (molecular or cytogenetic) by 1 year of diagnosis with therapy (imatinib mesylate or interferon)
    • Have a rising quantitative bcr/abl on imatinib mesylate (molecular relapse)
    • Had developed accelerated phase regardless of therapy but are now back in second chronic phase
  • Patients with recurrent solid tumors (neuroblastoma, Ewing's sarcoma, melanoma, rhabdomyosarcoma)
  • Patients with myelodysplastic syndrome
  • Patients with refractory anemia (RA) and refractory anemia with excess blasts (RAEB) are eligible, but refractory anemia with excess blasts in transformation (RAEB-T) patients are only eligible if treated to < 20% blasts with chemotherapy
  • Patients with selected immunodeficiencies such as Wiskott-Aldrich syndrome or hyper-IgM syndrome
  • Patients with metabolic diseases such as Niemann-Pick or adrenoleukodystrophy
  • Patients with bone marrow failure syndromes, including aplastic anemia
  • Adequate venous access

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00179790

United States, Illinois
Ann & Robert H Lurie Children's Hospital of Chicago
Chicago, Illinois, United States, 60625
Sponsors and Collaborators
Ann & Robert H Lurie Children's Hospital of Chicago
Principal Investigator: Jennifer Schneiderman, MD, MS Ann & Robert H Lurie Children's Hospital of Chicago

Responsible Party: Jennifer Schneiderman, MD, Attending Physician, Hematology, Oncology,Cell Transplantation, Ann & Robert H Lurie Children's Hospital of Chicago Identifier: NCT00179790     History of Changes
Other Study ID Numbers: ECP RIT
First Posted: September 16, 2005    Key Record Dates
Last Update Posted: March 6, 2017
Last Verified: March 2017

Keywords provided by Jennifer Schneiderman, MD, Ann & Robert H Lurie Children's Hospital of Chicago:
immune deficiency
extracorporeal photopheresis